The Valley Desk

NCT03580655 · Interventional trial

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Overall registry status Completed

Phase 2

Conditions Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis With an Associated Hematologic Neoplasm

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov